The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShire Regulatory News (SHP)

  • There is currently no data for SHP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) - Replacement of Shire plc

13 Dec 2018 16:19

RNS Number : 4459K
Morgan Stanley Capital Services LLC
13 December 2018
 

AMENDMENT Section (2b)

 

 FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Morgan Stanley Capital Services LLC

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Shire plc

(c) Name of the party to the offer with which exempt principal trader is connected:

 

Shire plc

(d) Date dealing undertaken:

11 DECEMBER 2018

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

Yes - Takeda Pharmaceutical Company Limited

 

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

 The currency of all prices and other monetary amounts should be stated.

 

 

(a) Purchases and sales

 

 Class of relevant security

 Purchases/sales

 Total number of securities

 Highest price per unit paid/received

 Lowest price per unit paid/received

 ADR

 PURCHASES

 1,700

 170.4400 USD

 169.3300 USD

 ADR

 SALES

 840

 170.3800 USD

 169.2100 USD

 

 

(b) Cash-settled derivative transactions

 

 Class of relevant security

 Product description

e.g. CFD

 Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

 Number of reference securities

 Price per unit

 ADR

 CFD

 LONG

 100

 169.6500 USD

 ADR

 CFD

 LONG

 27

 169.7900 USD

 ADR

 CFD

 LONG

 803

 169.8231 USD

 ADR

 CFD

 LONG

 676

 169.8500 USD

 ADR

 CFD

 SHORT

 1,500

 169.6113 USD

 ADR

 CFD

 SHORT

 1,600

 169.6631 USD

 ADR

 CFD

 SHORT

 100

 170.1200 USD

 ADR

 CFD

 SHORT

 100

 170.1200 USD

 ADR

 CFD

 SHORT

 100

 170.4400 USD

 5p ordinary

 CFD

 LONG

 143

 45.0518 GBP

 5p ordinary

 CFD

 LONG

 730

 45.0905 GBP

 5p ordinary

 CFD

 LONG

 6,970

 45.0905 GBP

 5p ordinary

 CFD

 LONG

 18

 45.1355 GBP

 5p ordinary

 CFD

 SHORT

 42

 44.9335 GBP

 5p ordinary

 CFD

 SHORT

 192

 44.9335 GBP

 5p ordinary

 CFD

 SHORT

 18,382

 44.9466 GBP

 5p ordinary

 CFD

 SHORT

 4,595

 44.9466 GBP

 5p ordinary

 CFD

 SHORT

 2,230

 45.0436 GBP

 5p ordinary

 CFD

 SHORT

 50

 45.1168 GBP

 5p ordinary

 CFD

 LONG

 5,631

 57.5216 USD

 5p ordinary

 CFD

 SHORT

 3,953

 45.0046 GBP

 5p ordinary

 CFD

 SHORT

 3,340

 56.8428 USD

 5p ordinary

 CFD

 SHORT

 10,136

 57.2235 USD

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

 Class of relevant security

 Product description e.g. call option

 Writing, purchasing, selling, varying etc.

 Number of securities to which option relates

 Exercise price per unit

 Type e.g. American, European etc.

 Expiry date

 Option money paid/ received per unit

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 

(ii) Exercise

 

 Class of relevant security

 Product description e.g. call option

 Number of securities

 Exercise price per unit

 N/A

 N/A

 N/A

 N/A

 

(d) Other dealings (including subscribing for new securities)

 

 Class of relevant security

 Nature of dealing e.g. subscription, conversion

 Details

 Price per unit (if applicable)

 N/A

 N/A

 N/A

 N/A

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

 

Date of disclosure:

13 DECEMBER 2018

Contact name:

Craig Horsley

Telephone number:

+44(141) 245 7736

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FERFKNDDABDDPBD
Date   Source Headline
8th Jan 20195:30 pmGNWDirector/PDMR Shareholding
8th Jan 20193:20 pmRNSForm 8.3 - Shire plc
8th Jan 20193:19 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
8th Jan 20193:13 pmRNSForm 8.3 - Shire plc
8th Jan 20193:07 pmRNSForm 8.5 (EPT/NON-RI)
8th Jan 20192:28 pmRNSForm 8.5 (EPT/RI) - Replacement of Shire
8th Jan 20192:23 pmRNSForm 8.5 (EPT/RI) - Replacement of Shire
8th Jan 20192:21 pmRNSForm 8.5 (EPT/RI) - Replacement of Shire
8th Jan 20191:57 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
8th Jan 20191:27 pmRNSForm 8.3 - Shire plc
8th Jan 201912:31 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
8th Jan 201912:29 pmRNSForm 8.3 - Takeda Pharmaceutical
8th Jan 201912:27 pmRNSForm 8.3 - Shire plc
8th Jan 201911:42 amRNSForm 8.5 (EPT/NON-RI)
8th Jan 201911:33 amRNSForm 8.5 (EPT/NON-RI)- Shire Plc
8th Jan 201910:49 amRNSForm 8.5 (EPT/RI)
8th Jan 201910:41 amRNSForm 8.3 - Takeda Pharmaceutical Company Limited
8th Jan 201910:26 amRNSForm 8.5 (EPT/RI)- Shire plc
8th Jan 20199:51 amRNSForm 8.3 - Shire Plc
8th Jan 20198:44 amRNSForm 8.5 (EPT/RI) - SHIRE PLC
8th Jan 20197:00 amRNSForm 8.3 - Takeda Pharmaceutical Company Limited
8th Jan 20197:00 amGNWScheme becomes effective
7th Jan 20195:00 pmGNWHolding(s) in Company
7th Jan 20193:42 pmRNSForm 8.5 (EPT/RI) - Amendment
7th Jan 20193:20 pmRNSForm 8.3 - Shire plc
7th Jan 20193:02 pmRNSForm 8.3 - Shire plc
7th Jan 20193:00 pmRNSForm 8.5 (EPT/NON-RI)
7th Jan 20193:00 pmRNSForm 8.3 - Shire plc
7th Jan 20192:59 pmRNSForm 8.3 - Takeda Pharmaceutical
7th Jan 20192:50 pmPRNForm 8.3 - Shire Plc
7th Jan 20192:49 pmRNSForm 8.3 - Shire plc
7th Jan 20192:47 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
7th Jan 20192:45 pmBUSForm 8.3 - Shire plc
7th Jan 20191:55 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
7th Jan 20191:54 pmRNSForm 8.3 - Shire plc
7th Jan 20191:39 pmRNSForm 8.3 - [Shire Plc]
7th Jan 20191:32 pmRNSForm 8.5 (EPT/RI) - Replacement of Shire
7th Jan 20191:29 pmRNSForm 8.5 (EPT/RI) - Replacement of Shire
7th Jan 201912:57 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
7th Jan 201912:56 pmRNSForm 8.3 - Shire plc
7th Jan 201912:42 pmRNSForm 8.5 (EPT/NON-RI)
7th Jan 201911:52 amRNSForm 8.3 - Takeda Pharmaceutical Company Limited
7th Jan 201911:43 amBUSForm 8.3 - SHIRE PLC
7th Jan 201911:30 amRNSForm 8.3 - Takeda Pharmaceutical Company Limited
7th Jan 201911:27 amRNSForm 8.3 - Shire plc
7th Jan 201911:01 amRNSForm 8.5 (EPT/RI)- Shire plc
7th Jan 201910:59 amRNSForm 8.5 (EPT/NON-RI)- Shire Plc
7th Jan 201910:35 amRNSForm 8.5 - Shire plc
7th Jan 201910:16 amRNSForm 8.5 (EPT/RI) - SHIRE PLC
7th Jan 201910:13 amRNSForm 8.5 (EPT/RI) - Amendment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.